Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

used in determining our GAAP diluted net income  (loss) per share. A reconciliation between GAAP and non-GAAP adjusted measures is provided in the Selected Financial Information – Non-GAAP Financial Measures Reconciliation table included with this release. The Company believes that its presentation of historical non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. These historical non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. Generally Accepted Accounting Principles.

Research and Development ProgramsViroPharma is investing in research and development programs to ensure growth for the future.  The current pipeline includes programs in various stages of clinical and pre-clinical development focused on rare diseases and serious unmet medical needs.

  • Subcutaneous administration of Cinryze – In December 2012, we initiated a Phase 2b double blind, multi-center, dose ranging study to evaluate the safety and efficacy of subcutaneous administration of in combination with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) in adolescents and adults with HAE for prevention of HAE attacks.  We expect to complete enrollment in this study during the first week of May, 2013.
  • New uses for C1 INH - We are investigating potential new uses for our C1 esterase inhibitor product with a goal of pursuing additional indications in patient populations with other C1 INH mediated diseases.  To that end, we are supporting investigator-initiated studies (IISs) evaluating C1 INH as a treatment for patients with Neuromyelitis Optica (NMO) and Autoimmune Hemolytic Anemia (AIHA); both of these studies were initiated in 2012. We are also conducting a clinical trial in Antibody-Mediated Rejection (AMR) post renal transplantation and are evaluating the pote
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Participate in Two December Healthcare Investor Conferences
    2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
    3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    8. WuXi PharmaTech Announces Third-Quarter 2011 Results
    9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    10. Spherix Announces Third Quarter Financial Results
    11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
    (Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
    (Date:12/25/2014)... (PRWEB) December 25, 2014 The report ... by Product Type & Provider Type - Global Advancements, ... market with an in-depth analysis and forecasting of revenues. ... spread through 221 pages and in-depth TOC on “Service ...
    (Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
    Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
    ... Sept. 13 Cephalon, Inc. (Nasdaq:,CEPH) today ... patient selection, dosing and administration for FENTORA(R),(fentanyl ... this information,with the medical community to reinforce ... The letter, issued in collaboration with ...
    ... thinkers and senior executives from companies and government organizations ... ... Sept. 13 In the foreseeable future a,trip to the ... is today. Armed with our complete genetic profile information about,predisposition ...
    ... Ala., Sept. 13 Southern Research,Institute today announced ... known as SR9025, to Virium Pharmaceuticals, Inc. To ... FDA approval and are on,the market. Six others, ... in early clinical trials. (Photo: http://www.newscom.com/cgi-bin/prnh/20070913/DCTH022 ...
    Cached Biology Technology:Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 2Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 3Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 4Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 5The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco 2Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals 2
    (Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... growing mobile commerce market, announces it has retained famous pickpocket, ... 2015 International CES debut of the Wocket™ biometric smart wallet.  ... the NXT-ID booth January 6th and 7 th , 2015, ...
    (Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
    (Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
    Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
    ... never good for you, but washing that meal down with ... of Guelph study. Researcher Marie-Soleil Beaudoin has discovered not ... eating a high-fat meal, but that the spike doubles after ... to levels similar to those of people at risk for ...
    ... Durham, NC ,Outer, tree canopy leaves influence the sunlight ... new study. The shape and physiology of leaves within ... on their position within the tree crown. This phenomenon is ... stress and use resources. A new study describes ...
    ... older doesn,t mean giving up muscle strength. Not only ... comes with age, but the Golden Years can be a time ... System. "Resistance exercise is a great way to ... function more readily in daily life," says Mark Peterson, Ph.D., a ...
    Cached Biology News:Got a craving for fast food? Skip the coffee, study says 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 3Older and stronger: Progressive resistance training can build muscle, increase strength as we age 4
    ...
    ... Columbus is a flexible, fully automated microplate strip ... to its fully automated microplate strip washing capability, ... and ease of operation. , ... include manifolds of 8, 12 or 16 channels, ...
    ... Sulfo SBED Protein:Protein Interaction Reagent A ... has rapidly gained traction as an in ... growing number of publications feature the exclusive ... to study a variety of issues relating ...
    ... Incubator is a compact benchtop and ... microprocessor controller with a large display ... agitation speed. Air circulation inside to ... Temperature can be easily calibrated from ...
    Biology Products: